Health-related quality of life measurement in asthma and chronic obstructive pulmonary disease: Review of the 2009-2014 literature

Multidisciplinary Respiratory Medicine

Volumn 11, Issue 1, 2016, Pages

  Arpinelli, Fabio ^a   Carone, Mauro ^b   Riccardo, Gioacchino ^a   Bertolotti, Giorgio ^b  

^a GSK   (Italy)

^b IRCCS   (Italy)

Author keywords

Asthma quality of life questionnaire; Asthma, COPD; Health related quality of life; Saint George's respiratory questionnaire

Indexed keywords

ACLIDINIUM BROMIDE; BECLOMETASONE; BUDESONIDE; BUDESONIDE PLUS TIOTROPIUM BROMIDE; FLUTICASONE; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; GLUCOCORTICOID; GLYCOPYRRONIUM BROMIDE; GLYCOPYRRONIUM BROMIDE PLUS INDACATEROL; INDACATEROL; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE; UMECLIDINIUM; UMECLIDINIUM PLUS VILANTEROL; UNCLASSIFIED DRUG; VILANTEROL;

ADD ON THERAPY; ASTHMA; ASTHMA QUALITY OF LIFE QUESTIONNAIRE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DAILY LIFE ACTIVITY; DRUG EFFICACY; EMPHYSEMA; HEALTH STATUS; HUMAN; MEDICAL LITERATURE; PSYCHOMETRY; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SAINT GEORGE RESPIRATORY QUESTIONNAIRE; SCORING SYSTEM; STATISTICAL ANALYSIS; WELLBEING;

EID: 84958034368     PISSN: 1828695X     EISSN: 20496958     Source Type: Journal    
DOI: 10.1186/s40248-016-0040-9     Document Type: Review

References (44)

1. Global Strategy for Asthma Management and Prevention (updated 2012) at www.ginasthma.org. Accessed 22 Apr 2014
2. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (updated 2014) at www.goldcopd.org. Accessed 22 Apr 2014
3. Agusti A, Calverley P, Celli B, Coxson HA, Edwards LD, Lomas DA, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11:122
4. Patrick DL, Burke LB, Powers JN, Scott JA, Rock E.P., Dawisha S, et al. Patient-Reported Outcomes to support Medical Product Labelling claims: FDA perspective. Value Health. 2007;10(s2):125-37
5. Guidance for Industry. Patient-Reported Outcome Measures: Use in Medical Products Development to Support Labeling Claims. Silver Spring, MD: US Department of Health and Human Services Food and Drug Administration 2009
6. Reflection Paper on the Regulatory Guidance for the Use of Health-related Quality of Life Measures in the Evaluation of Medicinal Products.European Medical Agency 2005 at http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003637.pdf. Accessed 18 apr 2014
7. Worth A, Hammersley VS, Nurmatov U, Sheikh A. Systematic literature review and evaluation of patient reported outcome measures (PROMs) for asthma and related allergic diseases. Prim Care Respir J. 2012;21(4):455-8
8. Juniper EF, Buist AS, Cox FM, Ferrie PJ, King DR. Validation of a standardized version of the Asthma Quality of Life Questionnaire. Chest. 1999;115:1265-70
9. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The Saint George Respiratory Questionnaire. Am Rev Respir Dis. 1992;145:1321-7
10. O'Connor RD, Patrick DL, Parasuraman B, Martin P, Goldman M. Comparison of Patient-reported outcomes during treatment with adjustable- and fixed-dose budesonide/formoterol pressurized merered-dose inhaler versus fixed-dose fluticasone propionate/salmeterol dry powder inhaler in patients with asthma. J Asthma. 2010;47:217-23
11. Jones PW, Singh D, Bateman ED, Agusti A, Lamarca R, de Miquel G, et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J. 2012;40:830-6
12. Dalby RN, Eicher J, Zierenberg B. Development of Respimat Soft Mist Inhaler and its clinical utility in respiratory disorders. Med Devices Evid Res. 2011;4:145-55
13. Bodzenta-Lukaszyk A, Pulka G, Dymec A, Bumbacea D, McIver T, Schwab B, et al. Efficacy and safety of fluticasoene and formoterol in a single pressurized metered dose inhaler. Respir Med. 2011;105:674-82
14. Bodzenta-Lukaszyk, Buhl R, Balint B, Lomax M, Spooner K, Dissanayake S. Fluticasone /formoterol combination therapy versus Budesonide/formoterol for the treatment of asthma: a randomized, controller, non-inferiority trial of efficay and safety. J Asthma. 2012;49(10):1060-70
15. Bodzenta-Lukaszyk A, van Noord J, Schroder-Babo W, McAulay K, McIver T. Efficacy and safety profile of fluticasone/formoterol combination therapy compared to its individual components administered concurrently in asthma: a randomised controller trial. Curr Med Res Opin. 2013;29(5):579-88
16. Kerstjiens HAM, Disse B, Schroder-Babo W, Bantie TA, Gahlemann M, Sigmund R, et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J Allerg Clin Immunol. 2011;128, 2:308-14
17. Kerstjens HAM, Engel M, Dahl R, Paggiaro P, Beck E, Vanderwalker M, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012;367:1198-207
18. Louis R, Joos G, Michils A, Vandenhoven G. A comparison of budesonide/formoterol maintenance and relieve therapy vs conventional best practice in asthma management. Int J Clin Pract. 2009;63 10:1479-88
19. Peters SP, Kunselman SJ, Icitovic N, Moore WC, Pascual R, Ameredes BT, et al. Tiotropium bromide step-up therapy for adult with uncontrolled asthma. N Engl J Med. 2010;363 18:1715-26
20. O'Byrne PM, Bleecker ER, Bateman ED, Busse WW, Woodcock A, Forth R, et al. Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma. Eur Respir J 2014;43:773-82
21. Woodcock A, Bleecker ER, Lotvall J, O'Byrne PM, Bateman ED, Medley H et, et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma. Chest. 2013;144(4):1222-9
22. Bateman ED, Kornmann O, Schmidt P, Pivovarova A, Engel M, Fabbri LM. Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. J Allergy Clin Immunol. 2011;128:315-22
23. Kerwin EM, D'Urzo AD, Gelb AF, Lakkis H, Garcia Gil E, Caracta CF. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD. 2012;9:90-101
24. Gelb AF, Tashkin DP, Make BJ, Zhong X, Garcai Gil E, Caracta CF. Long-term safety and efficacy of twice-daily aclidinium bromide in patients with COPD. Respir Med. 2013;107:1957-65
25. D'Urzo A, Ferguson GT, van Noord JA, Hirata K, Martin C, Lu Y, et al. Efficacy and safety of once-daily NVA237 in patients with moderate to severe COPD: the GLOW1 trial. Respir Res. 2011;12:156
26. Kerwin E, Hebert J, Gallagher N, Martin C, Overend T, Alagappan VK, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J. 2012;40:1106-14
27. Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, et al. Efficacy of a new once-daily long acting β2- agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010;65:473-9
28. Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C, et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. 2011;37:273-9
29. Donohue JF, Fogarty C, Lotvall J, Mahler DA, Worth H, Yorgancioglu A, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease. Indacaterol versus Tiotropium. Am J Respir Crit Care Med. 2010;182:155-62
30. Buhl R, Dunn LJ, Disdier C, Lassen C, Amos C, Henley M, et al. Blinded 12-week comparison of once-daily indacaterolo and tiotropium in COPD. Eur Respir J. 2011;38:797-803
31. Decramer ML, Chapman KR, Dahl R, Frith P, Devouassoux G, Fritscher C, et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomized, blinded parallel- group study. Lancet Respir Med. 2013;1:524-33
32. Bateman ED, Tashkin D, Siafakas N, Dahl R, Towse L, Massey D, et al. A one year trial of tiotropium Respimat plus usual therapy in COPD patients. Respir Med. 2010;104:1460-72
33. Fujimoto K, Kitaguchi Y, Kanda S, Urushihata K, Hanaoka M, Kubo K. Comparison of efficacy of long-acting bronchodilators in emphysema dominant and emphysema nondominant chronic obstructive pulmonary disease. Int J COPD. 2011;6:219-27
34. Hoshino M, Ohtawa J. Effect of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease. Respirology. 2011;16:95-101
35. Trivedi R, Richard N, Metha R, Church A. Umeclidinium in patients with COPD: a randomized, placebo-controlled study. Eur Respir J. 2014;43:72-81
36. Calverley PMA, Kuna P, Monso' E, Costantini M, Petruzzelli S, Sergio F, et al. Beclomethasone/formoterol in the management of COPD: a randomized controlled trial. Respir Med. 2010;104:1858-68
37. Welte T, Miravittles M, Hernandez P, Eriksson G, Peterson S, Polanowski T, et al. Efficacy and tolerability of Budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180:741-50
38. Sharafkhaneh A, Southard JG, Goldman M, Uryniak T, Martin UJ. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double blind randomized study. Respir Med. 2012;106:2257-268
39. Vogelmeier CF, Bateman ED, Pallante J, Alagappan VK, D'Andrea P, Chen H, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomized, double-blind, parallel group study. Lancet Respir Med. 2013;1:51-60
40. Wedzicha JA, Decramer M, Ficker JH, Niewoehner DE, Sandstrom T, Taylor AF, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomized, double-blind, parallel group study. Lancet Respir Med. 2013;1:199-209
41. Vincken W, Aumann J, Chen H, Henley M, McBryan D, Goyal P. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study. Int J COPD. 2014;9:215-28
42. Singh D, Nicolini G, Bindi E, Corradi M, Guastalla D, Kampschulte J, et al. Extrafine beclomethasone/formoterol compared to fluticasone/salmeterol combination therapy in COPD. BMC Pulm Med. 2014;14:43
43. Donohue JF, Maleki-Yazdi MR, Kilbride S, Metha R, Kalberg C, Church A. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med. 2013;107:1538-46
44. Celli B, Crater G, Kilbride S, Metha R, Tabberer M, Kalberg C, et al. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest. 2014;14585:981-91.